

1/28/10

02-02-2010

RECEIVED  
U.S. DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office



SHEET  
-Y

JAN 29 2010

103588083

To the Director of the U. S. Pa

ached documents or the new address(es) below.

1. Name of conveying party(ies):

SUNEVA MEDICAL, INC.

- Individual(s)
- General Partnership
- Corporation- State: Delaware
- Other \_\_\_\_\_
- Association
- Limited Partnership

Citizenship (see guidelines) \_\_\_\_\_

Additional names of conveying parties attached?  Yes  No

3. Nature of conveyance )/Execution Date(s) :

Execution Date(s) 11/25/09

- Assignment
- Security Agreement
- Other \_\_\_\_\_
- Merger
- Change of Name

2. Name and address of receiving party(ies)

Additional names, addresses, or citizenship attached?  Yes  No

Name: Venture Lending & Leasing V, Inc.

Internal

Address: \_\_\_\_\_

Street Address: 2010 North First Street

City: San Jose

State: CA

Country: US Zip: 95131

- Association Citizenship \_\_\_\_\_
- General Partnership Citizenship \_\_\_\_\_
- Limited Partnership Citizenship \_\_\_\_\_
- Corporation Citizenship Maryland
- Other \_\_\_\_\_ Citizenship \_\_\_\_\_

If assignee is not domiciled in the United States, a domestic representative designation is attached:  Yes  No  
(Designations must be a separate document from assignment)

4. Application number(s) or registration number(s) and identification or description of the Trademark.

A. Trademark Application No.(s)

B. Trademark Registration No.(s)

2,944,130; 2,802,661; 2,753,465; 2,973,136; 3,310,040; 3,357,323; 3,357,322

Additional sheet(s) attached?  Yes  No

C. Identification or Description of Trademark(s) (and Filing Date if Application or Registration Number is unknown):

5. Name & address of party to whom correspondence concerning document should be mailed:

Name: Jeffrey T. Klugman

Internal Address: \_\_\_\_\_

Street Address: 4 Embarcadero Center, Suite 4000

City: San Francisco

State: CA Zip: 94111

Phone Number: 415-981-1400

Fax Number: 415-777-4961

Email Address: \_\_\_\_\_

6. Total number of applications and registrations involved:

7

7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$ 190.00

- Authorized to be charged to deposit account
- Enclosed

8. Payment Information:

02/01/2010 LMUELLER 00000021 2944130

Deposit Account Number \_\_\_\_\_ 40.00

Authorized User Name \_\_\_\_\_ 150.00

9. Signature:

Signature

1/28/10

Date

Jeffrey T. Klugman  
Name of Person Signing

Total number of pages including cover sheet, attachments, and document: 14

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to: Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450

ORIGINAL

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this "Agreement") is made as of November 25, 2009, by and between SUNEVA MEDICAL, INC., a Delaware corporation ("Grantor"), and VENTURE LENDING & LEASING V, INC., a Maryland corporation ("Secured Party").

RECITALS

A. Pursuant to that certain Loan and Security Agreement of even date herewith between Grantor, as borrower, and Secured as lender (as amended, restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), Secured Party has agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the "Loans") in the amounts and manner set forth in the Loan Agreement. All capitalized terms used herein without definition shall have the meanings ascribed to them in the Loan Agreement.

B. Secured Party is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Secured Party a security interest in substantially all of Grantor's personal property whether presently existing or hereafter acquired. To that end, Grantor has executed in favor of Secured Party the Loan Agreement granting a security interest in all Collateral, and is executing this Agreement with respect to certain items of Intellectual Property, in particular.

NOW, THEREFORE, THE PARTIES HERETO AGREE AS FOLLOWS:

1. Grant of Security Interest. As collateral security for the prompt and complete payment and performance of all of Grantor's present or future Obligations, Grantor hereby grants a security interest and mortgage to Secured Party, as security, in and to Grantor's entire right, title and interest in, to and under the following Intellectual Property, now owned or hereafter acquired by Grantor or in which Grantor now holds or hereafter acquires any interest (all of which shall collectively be called the "Collateral" for purposes of this Agreement):

(a) Any and all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof or of any other country; all registrations, applications and recordings in the United States Copyright Office or in any similar office or agency of the United States, and State thereof or any other country; all continuations, renewals, or extensions thereof; and any registrations to be issued under any pending applications, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) All letters patent of, or rights corresponding thereto in, the United States or any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto in, the United States or any other country, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country; all reissues, continuations, continuations-in-part or extensions thereof; all petty patents, divisionals, and patents of addition; and all patents to be issued under any such applications, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(c) All trademarks, trade names, corporate names, business names, trade styles, service marks, logos, other source or business identifiers, prints and labels on which any of the foregoing have appeared or appear, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and any applications in connection therewith, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of

the United States, any State thereof or any other country or any political subdivision thereof, and reissues, extensions or renewals thereof, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(d) Any and all claims for damages by way of past, present and future infringement of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(e) All licenses or other rights to use any of the Copyrights, Patents or Trademarks, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(f) All amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents; and

(g) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing the term "Collateral" shall not include: (a) "intent-to-use" trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, but only to the extent the granting of a security interest in such "intent to use" trademarks would be contrary to applicable law; (b) any non-US regulatory approvals or similar authorizations, however called, nor any intellectual property rights including, without limitation, trade secrets, Copyrights, Patents, Trademarks and any contract related thereto arising from a joint venture, strategic alliance, licensing or similar arrangement entered into on or after the date hereof with a third-party who is not a Related Person; provided, however; that such exclusion shall not apply to commercial uses of the Borrower's Artefill product in the United States; and (c) any contract, instrument or chattel paper in which Grantor has any right, title or interest if and to the extent such contract, instrument or chattel paper includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of Grantor therein would be prohibited and would, in and of itself, cause or result in a default thereunder enabling another person party to such contract, instrument or chattel paper to enforce any remedy with respect thereto; provided, however, that the foregoing exclusion shall not apply if (i) such prohibition has been waived or such other person has otherwise consented to the creation hereunder of a security interest in such contract, instrument or chattel paper, or (ii) such prohibition would be rendered ineffective pursuant to Sections 9-407(a) or 9-408(a) of the UCC, as applicable and as then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code) or principles of equity); provided further that immediately upon the ineffectiveness, lapse or termination of any such provision, the term "Collateral" shall include, and Grantor shall be deemed to have granted a security interest in, all its rights, title and interests in and to such contract, instrument or chattel paper as if such provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect Secured Party's unconditional continuing security interest in and to all rights, title and interests of Grantor in or to any payment obligations or other rights to receive monies due or to become due under any such contract, instrument or chattel paper and in any such monies and other proceeds of such contract, instrument or chattel paper.

2. Covenants and Warranties. Grantor represents, warrants, covenants and agrees as follows:

(a) Grantor has rights (as defined in the UCC) in the Collateral, except for Permitted Liens;

(b) During the term of this Agreement, Grantor will not transfer or otherwise encumber any interest in the Collateral, except for Permitted Liens and except for transfers otherwise permitted under the Loan Agreement;

(c) To its knowledge, each of the Patents is valid and enforceable, and no part of the Collateral has been judged invalid or unenforceable, in whole or in part, and no claim has been made that any part of the Collateral violates the rights of any third party;

(d) Grantor shall deliver to Secured Party within thirty (30) days of the last day of each fiscal year, a report signed by Grantor, in form reasonably acceptable to Secured Party, listing (i) any applications or registrations that Grantor has made or filed in respect of any patents, copyrights or trademarks constituting Collateral, (ii) the status of any outstanding applications or registrations in respect of any patents, copyrights or trademarks constituting Collateral and (iii) any material change in the composition of the Collateral;

(e) Grantor shall use reasonable commercial efforts to (i) protect, defend and maintain the validity and enforceability of the Trademarks, Patents and Copyrights constituting Collateral (ii) detect infringements of the Trademarks, Patents and Copyrights constituting Collateral and promptly advise Secured Party in writing of material infringements detected and (iii) not allow any material Trademarks, Patents or Copyrights constituting Collateral to be abandoned, forfeited or dedicated to the public unless Borrower deems it to be in the best interest of Borrower's business;

(f) Grantor shall apply for registration (to the extent not already registered) with the United States Patent and Trademark Office or the United States Copyright Office, as applicable: (i) those intellectual property rights listed on Exhibits A, B and C hereto within thirty (30) days of the date of this Agreement; and (ii) those additional intellectual property rights developed or acquired by Grantor from time to time in connection with any product or service, prior to the sale or licensing of such product or the rendering of such service to any third party (including without limitation revisions or additions to the intellectual property rights listed on such Exhibits A, B and C), except, in each case, with respect to such rights that Grantor determines in its sole but reasonable commercial judgment need not be registered to protect its own business interests. Grantor shall, from time to time, execute and file such other instruments, and take such further actions as Secured Party may reasonably request from time to time to perfect or continue the perfection of Secured Party's interest in the Collateral. Grantor shall give Secured Party notice of all such applications or registrations; and

(g) Grantor shall not enter into any agreement that would materially impair or conflict with Grantor's obligations hereunder without Secured Party's prior written consent, which consent shall not be unreasonably withheld. Grantor shall not permit the inclusion in any material contract to which it becomes a party of any provisions that could or might in any way prevent the creation of a security interest in Grantor's rights and interests in any property included within the definition of the Collateral acquired under such contracts, except for provisions in such material contracts as are referenced in the last paragraph of Section 1 of this Agreement.

3. Further Assurances; Attorney in Fact.

(a) On a continuing basis, Grantor will make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation statements and collateral agreements and filings with the United States Patent and Trademark Office and the Register of Copyrights, and take all such action as may reasonably be deemed necessary or advisable, or as reasonably requested by Secured Party, to perfect Secured Party's security interest in all Copyrights, Patents and Trademarks and otherwise to carry out the intent and purposes of this Agreement, or for assuring and confirming to Secured Party the grant or perfection of a security interest in all Collateral.

(b) Grantor hereby irrevocably appoints Secured Party as Grantor's attorney-in-fact, with full authority in the place and stead of Grantor and in the name of Grantor, from time to time in Secured Party's discretion, to take any action and to execute any instrument which Secured Party may deem necessary or advisable to accomplish the purposes of this Agreement, including (i) to modify, in its sole discretion, this Agreement without

first obtaining Grantor's approval of or signature to such modification by amending Exhibits A, B and C, hereof, as appropriate, to include reference to any right, title or interest in any Copyrights, Patents or Trademarks acquired by Grantor after the execution hereof or to delete any reference to any right, title or interest in any Copyrights, Patents or Trademarks in which Grantor no longer has or claims any right, title or interest, (ii) to file, in its sole discretion, one or more financing or continuation statements and amendments thereto, relative to any of the Collateral without the signature of Grantor where permitted by law, and (iii) after the occurrence and during the continuance of an Event of Default, to transfer the Collateral into the name of Secured Party or a third party to the extent permitted under the California Uniform Commercial Code.

4. Events of Default. The occurrence of any of the following shall constitute an Event of Default under this Agreement:

(a) An Event of Default under the Loan Agreement; or

(b) Grantor breaches any warranty or agreement made by Grantor in this Agreement and, as to any breach that is capable of cure, Grantor fails to cure such breach within thirty (30) days of the sooner to occur of Grantor's receipt of notice of such breach from Secured Party or the date on which such breach first becomes known to Grantor.

5. Amendments. This Agreement may be amended only by a written instrument signed by both parties hereto, except for amendments permitted under Section 3 hereof to be made by Secured Party alone.

6. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument.

*[Signature Pages Follow]*

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year first above written.


GRANTOR:

Address of Grantor:

5870 Pacific Center Blvd.  
San Diego, CA 92121  
Attn: Chief Financial Officer

SUNEVA MEDICAL INC.

By:



Name: Niv Caviar

Its: CEO

**ORIGINAL**

SECURED PARTY:

Address of Secured Party:

2010 North First Street, Suite 310  
San Jose, CA 95131  
Attn: Chief Financial Officer

VENTURE LENDING & LEASING V, INC.

By: \_\_\_\_\_

Name: \_\_\_\_\_

Its: \_\_\_\_\_

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year first above written.

GRANTOR:

Address of Grantor:

SUNEVA MEDICAL, INC.

5870 Pacific Center Blvd.  
San Diego, CA 92121  
Attn: Chief Financial Officer

By: \_\_\_\_\_

Name: \_\_\_\_\_

Its: \_\_\_\_\_

 ORIGINAL

SECURED PARTY:

Address of Secured Party:

VENTURE LENDING & LEASING V, INC.

2010 North First Street, Suite 310  
San Jose, CA 95131  
Attn: Chief Financial Officer

By:  \_\_\_\_\_

Name: Jay Cohen

Its: Vice President

EXHIBIT A

Copyrights

Description

Registration Number

Registration Date

None

46109/0194  
JTK/370681.2

TRADEMARK  
REEL: 004142 FRAME: 0814



EXHIBIT B

Patents

See attachment

Patent Number	Application Number	Application Date	Country	Status	Grant Date	Title
5344452	07/572975	12/8/89	United States of America	Granted; PTE received; Expiration Date: 09/06/2016	9/6/94	ALLOPLASTIC IMPLANT
2455525	2455525	6/24/02	Canada	Inactive;* Restoration Deadline: 06/24/2010	12/4/07	ELONGATED SYRINGE
6926699	10/205597	7/24/02	United States of America	Granted	8/9/05	ELONGATED SYRINGE
6929623	10/992915	11/18/04	United States of America	Granted	8/16/05	ELONGATED SYRINGE
N/A	11/199683	8/8/05	United States of America	Pending	N/A	ELONGATED SYRINGE
N/A	11/325618	1/3/06	United States of America	Inactive;** Revival Deadline: 03/17/2011	N/A	INJECTION APPARATUS HAVING A PLURALITY OF STOPPERS
N/A	06717416.9	1/3/06	EPO	Pending	NA	INJECTION APPARATUS HAVING A PLURALITY OF STOPPERS
N/A	2589962	1/3/06	Canada	Inactive;* Restoration Deadline: 06/16/2010	N/A	INJECTION APPARATUS HAVING A PLURALITY OF STOPPERS
N/A	06717416.9	1/3/06	EPO	Pending	N/A	INJECTION APPARATUS HAVING A PLURALITY OF STOPPERS
N/A	11/45439	6/16/06	United States of America	Inactive;** Revival Deadline: 05/18/2011	N/A	LIFE-LIKE ANATOMIC FEATURE FOR TESTING INJECTION OF SOFT TISSUE FILLERS
N/A	2610592	6/16/06	Canada	Inactive;* Restoration Deadline: 06/19/2010	N/A	LIQUID CRYSTAL POLYMER SYRINGES AND CONTAINERS AND METHODS OF USE FOR LONG TERM STORAGE OF FILLER MATERIALS
N/A	11/454537	6/16/06	United States of America	Pending	N/A	LIQUID CRYSTAL POLYMER SYRINGES AND CONTAINERS AND METHODS OF USE FOR LONG TERM STORAGE OF FILLER MATERIALS
N/A	02744316.7	6/14/02	EPO	Inactive;* Restoration Deadline: 12/30/2009	N/A	MEDICAL INJECTION APPARATUS
6666848	10/172773	6/14/02	United States of America	Granted	12/23/03	MEDICAL INJECTION APPARATUS
N/A	2455326	6/14/02	Canada	Inactive;* Restoration Deadline: 06/15/2010	N/A	MEDICAL INJECTION APPARATUS
N/A	05790690.1	8/22/05	EPO	Inactive;* Restoration Deadline: 01/31/2010	N/A	METHODS OF ADMINISTERING MICROPARTICLES COMBINED WITH AUTOLOGOUS BODY COMPONENTS
7442389	11/210273	8/22/05	United States of America	Granted	10/28/08	METHODS OF ADMINISTERING MICROPARTICLES COMBINED WITH AUTOLOGOUS BODY COMPONENTS
N/A	2569736	8/22/05	Canada	Inactive;* Restoration Deadline: 12/27/2009	N/A	METHODS OF ADMINISTERING MICROPARTICLES COMBINED WITH AUTOLOGOUS BODY COMPONENTS

Patent Number	Application Number	Application Date	Country	Status	Grant Date	Title
N/A	12/179509	7/24/08	United States of America	Pending	N/A	METHODS OF ADMINISTERING MICROPARTICLES COMBINED WITH AUTOLOGOUS BODY COMPONENTS
N/A	11/546578	10/10/06	United States of America	Inactive;** Revival Deadline: 06/28/2011	N/A	NASO-PHARYNGEAL TISSUE ENGINEERING
N/A	11/454540	6/16/06	United States of America	Inactive;** Revival Deadline: 10/07/2010	N/A	TISSUE AUGMENTATION METHODS USING A MEDICAL INJECTION APPARATUS
6432045	09/825484	4/2/01	United States of America	Granted	8/13/02	URETHRA SURGICAL DEVICE
N/A	2404958	4/2/01	Canada	Inactive;* Restoration Deadline: 04/02/2010	N/A	URETHRA SURGICAL DEVICE

EXHIBIT C

Trademarks

See attachment

Mark	Country	Application No	Application Date	Registration Number	Registration Date	Status
ARTEFILL	United Arab Emirates	77414	2/7/06	62487	2/7/06	Registered
ARTEFILL	Canada	1150709	8/23/02	603607	3/1/04	Registered
ARTEFILL	Canada	1322865	11/3/06	N/A	N/A	Pending
ARTEFILL	China	3911719	2/16/04	3911719	11/28/05	Registered
ARTEFILL	European Union	1539584	2/29/00	1539584	6/13/01	Registered
ARTEFILL	Israel	174291	8/22/04	174291	2/8/06	Registered
ARTEFILL	Japan	2004-057456	6/22/04	4852729	4/1/05	Registered
ARTEFILL	Korea (South)	40-2004-7138	2/18/04	629029	8/24/05	Registered
ARTEFILL	Mexico	564629	9/5/02	767246	10/31/02	Registered
ARTEFILL	United States of America	75/788742	8/31/99	2944130	4/26/05	Registered
ARTES	United States of America	75/862435	12/2/99	2802661	1/6/04	Registered
ARTES MEDICAL	European Union	1544071	3/2/00	1544071	6/11/02	Registered
ARTES MEDICAL	United States of America	75/862811	12/2/99	2753465	8/19/03	Registered
UROSCOPE	European Union	2016269	12/22/00	2016269	2/3/03	Registered
UROSCOPE	Mexico	465433	1/11/01	720662	10/30/01	Registered
ARTEFLUX	European Union	2016335	12/22/00	2016335	6/20/02	Registered
ARTEFLUX	Mexico	465432	1/11/01	720661	10/30/01	Registered
GASTROFLUX	Mexico	466410	1/17/01	725590	11/30/01	Registered
THE ART OF SOFT TISSUE AUGMENTATION	European Union	2069037	2/2/01	2069037	3/10/04	Registered
THE ART OF SOFT TISSUE AUGMENTATION	Mexico	469518	2/6/01	731143	1/30/02	Registered
ENDURING BEAUTY	Australia	949457	4/3/03	949457	4/3/03	Registered
ENDURING BEAUTY	China	3540051	4/25/03	3540051	10/21/04	Registered
ENDURING BEAUTY	European Union	3119377	4/3/03	3119377	7/21/05	Registered
ENDURING BEAUTY	Japan	2003-63126	7/28/03	4783723	7/2/04	Registered
ENDURING BEAUTY	United States of America	78/231347	3/28/03	2973136	7/19/05	Registered
ARTEGEN	European Union	4296166	2/18/05	4296166	5/29/06	Registered
AESTHETIC TISSUE ENGINEERING	European Union	4425419	5/5/05	4425419	6/22/06	Registered
THE FIRST TO LAST	United States of America	78/978480	1/11/05	3310040	10/9/07	Registered
PURIFIED BOVINE COLLAGEN	United Arab Emirates	77415	2/7/06	62486	8/23/06	Registered
PRECISION-FILTERED MICROSPHERES	United Arab Emirates	77417	2/7/06	62484	2/7/06	Registered
ARTEFILL THE FIRST TO LAST	United Arab Emirates	77418	2/7/06	77319	2/7/06	Registered
ARTEFILL THE FIRST TO LAST	Australia	1097641	2/6/06	1097641	2/6/06	Registered
ARTEFILL THE FIRST TO LAST	Canada	1289053	2/7/06	N/A	N/A	Pending
ARTEFILL THE FIRST TO LAST	European Union	4886735	2/7/06	4886735	5/25/07	Registered
ARTEFILL THE FIRST TO LAST	Japan	2006-010803	2/9/06	5035551	3/30/07	Registered
ARTEFILL THE FIRST TO LAST	Korea (South)	40-2006-6794	2/9/06	690167	12/15/06	Registered
ARTEFILL THE FIRST TO LAST	Kuwait	75160	2/13/06	63022	2/13/06	Registered
ARTEFILL THE FIRST TO LAST	Mexico	765000	2/9/06	979964	4/13/07	Registered
ARTEFILL THE FIRST TO LAST	Mexico	798130	7/24/06	950227	8/3/06	Registered
ARTEFILL THE FIRST TO LAST	United States of America	78/689129	8/9/05	3357323	12/18/07	Registered
ARTEFILL THE FIRST TO LAST (words only)	United Arab Emirates	77419	2/7/06	77314	11/7/06	Registered
ARTEFILL THE FIRST TO LAST (DESIGN)	Australia	1097640	2/6/06	1097640	2/6/06	Registered
ARTEFILL THE FIRST TO LAST (DESIGN)	Canada	1289052	2/7/06	N/A	N/A	Pending
ARTEFILL THE FIRST TO LAST (DESIGN)	European Union	4885398	2/7/06	4885398	5/4/07	Registered
ARTEFILL THE FIRST TO LAST (DESIGN)	Kuwait	75161	2/13/06	62174	2/13/06	Registered

Mark	Country	Application No	Application Date	Registration Number	Registration Date	Status
ARTEFILL THE FIRST TO LAST (DESIGN)	Mexico	765001	2/9/06	979965	4/13/07	Registered
ARTEFILL THE FIRST TO LAST (DESIGN)	Mexico	798134	7/24/06	952437	8/3/06	Registered
ARTEFILL THE FIRST TO LAST (DESIGN)	United States of America	78/689110	8/9/05	3357322	12/18/07	Registered
ARTEFILL PROGRESSIVE ENHANCEMENT TREATMENT	Mexico	798128	7/24/06	948783	8/3/06	Registered
ARTEFILL AESTHETIC TISSUE ENGINEERING	Mexico	N/A	8/3/06	948785	8/3/06	Registered
ARTECOLL	United Kingdom	2042682	10/26/95	2042682	10/26/95	Registered
ARTECOLL	Israel	119179	4/20/98	119179	9/7/99	Registered
ARTECOLL	Canada	0801636	1/15/96	523113	2/15/00	Registered
ARTECOLL	Hong Kong	9805661	5/1/05	20000133	5/1/05	Registered
ARTECOLL	Australia	701850	2/7/96	701850	6/20/97	Registered
ARTECOLL	Thailand	302643	2/14/96	KOR53063	12/11/96	Registered
ARTECOLL	Serbia	N/A	N/A	612046	8/10/93	Registered
ARTECOLL (and Design)	Switzerland	10268/2001	10/24/01	494530	2/28/02	Registered
ARTECOLL (and Design)	Singapore	T01/16626H	10/24/01	T01/16626H	10/24/01	Registered
ARTES MEDICAL	European Union	5907142	5/15/07	5907142	7/24/08	Registered